A centuries-old herbal medicine, discovered by Chinese scientists and used to effectively treat malaria, has been found to potentially aid in the treatment of tuberculosis and may slow the evolution of drug resistance.
In a promising study led by Robert Abramovitch, a Michigan State University microbiologist and TB expert, the ancient remedy artemisinin stopped the ability of TB-causing bacteria, known as Mycobacterium tuberculosis, to become dormant. This stage of the disease often makes the use of antibiotics ineffective.
The study is published in the journal Nature Chemical Biology.
“When TB bacteria are dormant, they become highly tolerant to antibiotics,” Abramovitch said, an assistant professor in the College of Veterinary Medicine. “Blocking dormancy makes the TB bacteria more sensitive to these drugs and could shorten treatment times.”
One-third of the world’s population is infected with TB and the disease killed 1.8 million people in 2015, according to the Centers for Disease Control and Prevention.
Mycobacterium tuberculosis, or Mtb, needs oxygen to thrive in the body. The immune system starves this bacterium of oxygen to control the infection. Abramovitch and his team found that artemisinin attacks a molecule called heme, which is found in the Mtb oxygen sensor. By disrupting this sensor and essentially turning it off, the artemisinin stopped the disease’s ability to sense how much oxygen it was getting.
“When the Mtb is starved of oxygen, it goes into a dormant state, which protects it from the stress of low-oxygen environments,” Abramovitch said. “If Mtb can’t sense low oxygen, then it can’t become dormant and will die.”
Abramovitch indicated that dormant TB can remain inactive for decades in the body. But if the immune system weakens at some point, it can wake back up and spread. Whether it wakes up or stays ‘asleep’ though, he said TB can take up to six months to treat and is one of the main reasons the disease is so difficult to control.
“Patients often don’t stick to the treatment regimen because of the length of time it takes to cure the disease,” he said. “Incomplete therapy plays an important role in the evolution and spread of multi-drug resistant TB strains.”
He said the research could be key to shortening the course of therapy because it can clear out the dormant, hard-to-kill bacteria. This could lead to improving patient outcomes and slowing the evolution of drug-resistant TB.
After screening 540,000 different compounds, Abramovitch also found five other possible chemical inhibitors that target the Mtb oxygen sensor in various ways and could be effective in treatment as well.
“Two billion people worldwide are infected with Mtb,” Abramovitch said. “TB is a global problem that requires new tools to slow its spread and overcome drug resistance. This new method of targeting dormant bacteria is exciting because it shows us a new way to kill it. ”
Learn more: ANCIENT CHINESE MALARIA REMEDY FIGHTS TB
[osd_subscribe categories=’tuberculosis’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “TUBERCULOSIS”‘]
Receive an email update when we add a new TUBERCULOSIS article.
The Latest on: Tuberculosis
[google_news title=”” keyword=”tuberculosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Tuberculosis
- Japan's Princess Kiko tours historic Tokyo suburban tuberculosis treatment hubon May 1, 2024 at 12:35 am
Crown Princess Kiko, the wife of Crown Prince Akishino (Fumihito), on April 30 visited the suburban Tokyo city of Kiyose, which has historica ...
- The path to a better tuberculosis vaccine runs through Montanaon April 29, 2024 at 10:20 am
A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.
- Tuberculosis case in Corby school as health bosses begin screening 'close contacts'on April 29, 2024 at 7:36 am
A child at Brooke Weston Academy in Corby has received a diagnosis of tuberculosis. The illness is rarely seen in children in the UK and causes a persistent cough, a high temperature, weight loss, ...
- Harnessing immune enhancement to combat drug-resistant tuberculosison April 28, 2024 at 11:17 am
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- Enhancing Immunity to Combat Tuberculosison April 27, 2024 at 9:10 am
Researchers explore host-directed therapies, harnessing the body's immune system to combat tuberculosis, including drug-resistant strains.
- Experts develop immune-enhancing therapies to target tuberculosison April 26, 2024 at 3:13 pm
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- Revvity unveils a new era of automated tuberculosis testingon April 26, 2024 at 8:38 am
Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to ...
- Drug-resistant tuberculosis responds rapidly to bedaquiline-based second-line therapy, claims studyon April 25, 2024 at 8:31 am
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking ...
- Excess tuberculosis deaths in the WHO European regionon April 24, 2024 at 5:14 pm
A new report from WHO and the ECDC says that 7000 estimated excess tuberculosis deaths in the WHO European region in 2020–22 were a direct result of the pandemic. Talha Burki reports.
via Bing News